Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Titles
NEW
 Top 50 Non-Healthcare Titles
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Cancer Monoclonal Antibodies Global Market Report 2025
Request Sample Buy Now
Global Cancer Monoclonal Antibodies Market Report 2025

Report Price : $4490.00

Pages : 250

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Cancer Monoclonal Antibodies Global Market Report 2025

By Monoclonal Antibody Therapies (Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others), By Application (Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others), By End-User (Hospitals, Research Laboratories, Others) – Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Cancer Monoclonal Antibodies Market?

Cancer monoclonal antibodies refer to a particular class of protein created in a lab that has the ability to bind to certain bodily targets, such as antigens on the surface of cancer cells. Each monoclonal antibody is designed to bind to a single antigen, and there are many different types of monoclonal antibodies.

The main types of monoclonal antibody therapies in cancer are bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different applications include Breast Cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and others, and involve various sectors such as hospitals and clinics, research laboratories, pharmacies, and others.

Cancer Monoclonal Antibodies Market 2025 - 2034

What Is The Cancer Monoclonal Antibodies Market Size 2025 And Growth Rate?

The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $77.88 billion in 2024 to $86.06 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to emerging markets growth, increase in R&D expenditure, increased geriatric population, and increased preference for biological treatments.

What Is The Cancer Monoclonal Antibodies Market Growth Forecast?

The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $113.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, expanding global access, and a rise in healthcare expenditure will drive the growth. Major trends in the forecast period include product innovation through strategic collaborations, technological advancements, developing humanized cancer monoclonal antibodies, investments in AI to reduce R&D costs and save drug development time, and R&D investments.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

How Is The Cancer Monoclonal Antibodies Market Segmented?

The cancer monoclonal antibodies market covered in this report is segmented –

1) By Monoclonal Antibody Therapies: Avastin, Herceptin, keytruda, Opdivo, Darzalex, Perjeta, Others

2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others

3) By End-User: Hospitals, Research Laboratories, Others

Subsegments:

1) By Avastin: Colorectal Cancer Treatment, Lung Cancer Treatment, Renal Cell Carcinoma Treatment

2) By Herceptin: Breast Cancer Treatment, Gastric Cancer Treatment

3) By Keytruda: Melanoma Treatment, Non-Small Cell Lung Cancer (NSCLC) Treatment, Head And Neck Cancer Treatment

4) By Opdivo: Melanoma Treatment, Renal Cell Carcinoma Treatment, Hodgkin Lymphoma Treatment

5) By Darzalex: Multiple Myeloma Treatment, AL Amyloidosis Treatment

6) By Perjeta: Breast Cancer Treatment, Neoadjuvant Therapy For HER2-Positive Breast Cancer

7) By Others: Cetuximab (Erbitux) For Colorectal And Head And Neck Cancers, Rituximab (Rituxan) For Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia, Atezolizumab (Tecentriq) For Various Cancers

What Is Driving The Cancer Monoclonal Antibodies Market? Cancer Monoclonal Antibody Market Driven By Rising Cancer Incidence Rates

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in Australia the number of cancer cases diagnosed increased from 160,570 in 2022 to 164,694 in 2023, reflecting a notable rise over the year. This upward trend highlights the growing prevalence of cancer within the country. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for growth of the cancer monoclonal antibody market.

What Is Driving The Cancer Monoclonal Antibodies Market? Rising Healthcare Expenditures Expected To Propel Cardiovascular Device Market Growth

Increasing healthcare expenditures are anticipated to propel the growth of the Cancer Monoclonal Antibodies market. Healthcare expenditures refer to the total amount spent on healthcare-related services, products, and activities within a specified period, typically on an individual, community, national, or global level. The higher funding in healthcare can support the development, accessibility, and research of monoclonal antibody treatments, while also enabling the adoption of advanced technologies for their production and delivery. For instance, in 2022, according to the Office for National Statistics, a UK-based national statistics organization, UK healthcare expenditure reached approximately $354.88 billion (£283 billion) in 2022, reflecting a nominal increase of 0.7% compared to spending in 2021. Therefore, increasing healthcare expenditure will drive the growth of the cancer monoclonal antibodies market going forward.

Who Are The Major Players In The Global Cancer Monoclonal Antibodies Market?

Major companies operating in the cancer monoclonal antibodies market include F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc, Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Gilead Sciences, Eurofarma, BIONOVIS BRASIL, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, 54Gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme

What Are The Key Trends Of The Global Cancer Monoclonal Antibodies Market? Collaborative Innovation To Develop Breakthrough Therapies

Companies in the cancer monoclonal antibody market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in March 2023, BioNTech SE, a Germany-based biotechnology research company, partnered with OncoC4, Inc. to jointly develop and market an innovative checkpoint antibody across various solid tumor indications. Through this partnership, BioNTech will obtain an exclusive worldwide license for the ONC-392 anti-CTLA-4 monoclonal antibody from OncoC4. Joint Development Planned for Solid Tumor Indications, Including a Phase 3 Trial in 2023 BioNTech to Explore Combination Therapies and Provide $200 Million Upfront Payment and Royalty Payments to OncoC4 with Potential Milestone OncoC4, Inc. is a US-based clinical-stage biopharmaceutical company specializing in biologicals for cancer treatment.

What Are The Key Trends Of The Global Cancer Monoclonal Antibodies Market? EPKINLY Advances Lymphoma Treatment

Companies operating in the cancer monoclonal antibodies market are focused on new biologic therapies such as EPKINLY to sustain their position in the market. EPKINLY is an FDA-approved bispecific antibody for advanced lymphoma treatment. For instance, in May 2023, AbbVie Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for EPKINLY (epcoritamab-bysp). It is the first and only T-cell engaging bispecific antibody designed for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) who have undergone two or more rounds of systemic therapies.

Need data on a specific region in this market?
Request Customisation

Cancer Monoclonal Antibodies Market Merger And Acquisition: Johnson and Johnson Acquires Ambrx to Strengthen Oncology Pipeline

In March 2024, Johnson & Johnson, a US-based multinational corporation that develops and manufactures medical devices and pharmaceuticals, acquired Ambrx for a $2 billion amount. With this acquisition, Johnson & Johnson aims to enhance its oncology pipeline by advancing next-generation antibody-drug conjugates, particularly for treating metastatic castration-resistant prostate cancer. Ambrx is a US-based biotechnology company that specializes in antibody drug conjugates.

Regional Outlook For The Global Cancer Monoclonal Antibodies Market

North America was the largest region in the cancer monoclonal antibodies market in 2024. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

What Defines the Cancer Monoclonal Antibodies Market?

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are """"factory gate values,"""" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Cancer Monoclonal Antibodies Industry?

The cancer monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cancer Monoclonal Antibodies Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $86.06 billion
Revenue Forecast In 2034 $113.68 billion
Growth Rate CAGR of 7.2% from 2024 to 2033
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Monoclonal Antibody Therapies: Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others
2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others
3) By End-User: Hospitals, Research Laboratories, Others Subsegments: 1) By Avastin: Colorectal Cancer Treatment, Lung Cancer Treatment, Renal Cell Carcinoma Treatment
2) By Herceptin: Breast Cancer Treatment, Gastric Cancer Treatment
3) By Keytruda: Melanoma Treatment, Non-Small Cell Lung Cancer (NSCLC) Treatment, Head And Neck Cancer Treatment
4) By Opdivo: Melanoma Treatment, Renal Cell Carcinoma Treatment, Hodgkin Lymphoma Treatment
5) By Darzalex: Multiple Myeloma Treatment, AL Amyloidosis Treatment 6) By Perjeta: Breast Cancer Treatment, Neoadjuvant Therapy For HER2-Positive Breast Cancer 7) By Others: Cetuximab (Erbitux) For Colorectal And Head And Neck Cancers, Rituximab (Rituxan) For Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia, Atezolizumab (Tecentriq) For Various Cancers
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc, Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Gilead Sciences, Eurofarma, BIONOVIS BRASIL, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, 54gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Cancer Monoclonal Antibodies Market Characteristics

3. Cancer Monoclonal Antibodies Market Trends And Strategies

4. Cancer Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cancer Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

5.1. Global Cancer Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Cancer Monoclonal Antibodies Market Growth Rate Analysis

5.4. Global Cancer Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Cancer Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Cancer Monoclonal Antibodies Total Addressable Market (TAM)

6. Cancer Monoclonal Antibodies Market Segmentation

6.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Avastin

Herceptin

Keytruda

Opdivo

Darzalex

Perjeta

Others

6.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Breast Cancer

Blood Cancer

Lung Cancer

Brain Tumor

Colorectal Cancer

Cervical Cancer

Gastric Cancer

Others

6.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Research Laboratories

Others

6.4. Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Avastin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Colorectal Cancer Treatment

Lung Cancer Treatment

Renal Cell Carcinoma Treatment

6.5. Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Herceptin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Breast Cancer Treatment

Gastric Cancer Treatment

6.6. Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Keytruda, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Melanoma Treatment

Non-Small Cell Lung Cancer (NSCLC) Treatment

Head And Neck Cancer Treatment

6.7. Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Opdivo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Melanoma Treatment

Renal Cell Carcinoma Treatment

Hodgkin Lymphoma Treatment

6.8. Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Darzalex, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Multiple Myeloma Treatment

AL Amyloidosis Treatment

6.9. Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Perjeta, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Breast Cancer Treatment

Neoadjuvant Therapy For HER2-Positive Breast Cancer

6.10. Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cetuximab (Erbitux) For Colorectal And Head And Neck Cancers

Rituximab (Rituxan) For Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia

Atezolizumab (Tecentriq) For Various Cancers

7. Cancer Monoclonal Antibodies Market Regional And Country Analysis

7.1. Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Monoclonal Antibodies Market

8.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Monoclonal Antibodies Market

9.1. China Cancer Monoclonal Antibodies Market Overview

9.2. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Monoclonal Antibodies Market

10.1. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Monoclonal Antibodies Market

11.1. Japan Cancer Monoclonal Antibodies Market Overview

11.2. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Monoclonal Antibodies Market

12.1. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Monoclonal Antibodies Market

13.1. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Monoclonal Antibodies Market

14.1. South Korea Cancer Monoclonal Antibodies Market Overview

14.2. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Monoclonal Antibodies Market

15.1. Western Europe Cancer Monoclonal Antibodies Market Overview

15.2. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Monoclonal Antibodies Market

16.1. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Monoclonal Antibodies Market

17.1. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Monoclonal Antibodies Market

18.1. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Monoclonal Antibodies Market

19.1. Italy Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Monoclonal Antibodies Market

20.1. Spain Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Monoclonal Antibodies Market

21.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview

21.2. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Monoclonal Antibodies Market

22.1. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Monoclonal Antibodies Market

23.1. North America Cancer Monoclonal Antibodies Market Overview

23.2. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Monoclonal Antibodies Market

24.1. USA Cancer Monoclonal Antibodies Market Overview

24.2. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Monoclonal Antibodies Market

25.1. Canada Cancer Monoclonal Antibodies Market Overview

25.2. Canada Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Monoclonal Antibodies Market

26.1. South America Cancer Monoclonal Antibodies Market Overview

26.2. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Monoclonal Antibodies Market

27.1. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Monoclonal Antibodies Market

28.1. Middle East Cancer Monoclonal Antibodies Market Overview

28.2. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Monoclonal Antibodies Market

29.1. Africa Cancer Monoclonal Antibodies Market Overview

29.2. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

30.1. Cancer Monoclonal Antibodies Market Competitive Landscape

30.2. Cancer Monoclonal Antibodies Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co., Inc Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Monoclonal Antibodies Market Other Major And Innovative Companies

31.1. AstraZeneca plc

31.2. Eli Lilly and Company

31.3. Pfizer Inc

31.4. Regeneron Pharmaceuticals Inc

31.5. Sanofi S.A

31.6. Innovent Biologics

31.7. Sino biological

31.8. Shanghai Henlius Biotech

31.9. Intas bio

31.10. Zydus Cadila

31.11. Ranbaxy

31.12. Takeda pharmaceuticals

31.13. AbbVie Inc

31.14. Biogen Idec

31.15. Bayer AG

32. Global Cancer Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

34. Recent Developments In The Cancer Monoclonal Antibodies Market

35. Cancer Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

35.1 Cancer Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities

35.2 Cancer Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities

35.3 Cancer Monoclonal Antibodies Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Avastin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Herceptin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Keytruda, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Opdivo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Darzalex, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Perjeta, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 82: Merck & Co., Inc Financial Performance
  • Table 83: Bristol Myers Squibb Company Financial Performance
  • Table 84: Johnson & Johnson Financial Performance
  • Table 85: Amgen Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Avastin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Herceptin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Keytruda, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Opdivo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Darzalex, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Perjeta, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Cancer Monoclonal Antibodies Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 82: Merck & Co., Inc Financial Performance
  • Figure 83: Bristol Myers Squibb Company Financial Performance
  • Figure 84: Johnson & Johnson Financial Performance
  • Figure 85: Amgen Inc Financial Performance

Antiobesity Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Antiobesity Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Antiobesity Market Landscape: Innovative Advancements In The Anti-Parkinson Drugs Market

Read More About Emerging Trends Redefining the Antiobesity Market Landscape: Innovative Advancements In The Anti-Parkinson Drugs Market

Top Trends Driving Innovation and Change in the Anti-Thyroid Drugs Market: Raising Awareness And Promoting Thyroid Health In The Anti-Thyroid Drug Market

Read More About Top Trends Driving Innovation and Change in the Anti-Thyroid Drugs Market: Raising Awareness And Promoting Thyroid Health In The Anti-Thyroid Drug Market

Market Trends Influencing Strategic Decisions in the Antivirals Industry: Innovative Oral Antiviral Treatments Enhancing Patient Compliance And Accessibility In The Fight Against Viral Infections

Read More About Market Trends Influencing Strategic Decisions in the Antivirals Industry: Innovative Oral Antiviral Treatments Enhancing Patient Compliance And Accessibility In The Fight Against Viral Infections

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Read More About Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Read More About Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Read More About Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Explore the impact of innovative phytocine lines on the herbal medicine market in 2025.

Read More About Explore the impact of innovative phytocine lines on the herbal medicine market in 2025.

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By ...

View Report

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Ho...

View Report

Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorde...

View Report

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

View Report

Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospi...

View Report

Gastrointestinal Drugs Global Market Report 2022 – By Type (Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals), By Distribution Channel (Hospital Pharmacies, Retai...

View Report

Hematology Drugs Global Market Report 2022 – By Type (Blood Products, Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administrat...

View Report

Metabolic Disorders Drugs Global Market Report 2022 – By Type (Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)), By Distribution Channel (Hospital Pharmacies, Retai...

View Report

Frequently Asked Questions

Cancer monoclonal antibodies refer to a particular class of protein created in a lab that has the ability to bind to certain bodily targets, such as antigens on the surface of cancer cells. Each monoclonal antibody is designed to bind to a single antigen, and there are many different types of monoclonal antibodies. For further insights on the Cancer Monoclonal Antibodies market, request a sample here

The Cancer Monoclonal Antibodies market major growth driver - Cancer Monoclonal Antibody Market Driven By Rising Cancer Incidence Rates. For further insights on the Cancer Monoclonal Antibodies market, request a sample here

The Cancer Monoclonal Antibodies market size has grown strongly in recent years. The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $77.88 billion in 2024 to $86.06 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to emerging markets growth, increase in R&D expenditure, increased geriatric population, and increased preference for biological treatments. The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $113.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, expanding global access, and a rise in healthcare expenditure will drive the growth. Major trends in the forecast period include product innovation through strategic collaborations, technological advancements, developing humanized cancer monoclonal antibodies, investments in AI to reduce R&D costs and save drug development time, and R&D investments. For further insights on the Cancer Monoclonal Antibodies market, request a sample here

The cancer monoclonal antibodies market covered in this report is segmented –
1) By Monoclonal Antibody Therapies: Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others
2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others
3) By End-User: Hospitals, Research Laboratories, Others Subsegments:
1) By Avastin: Colorectal Cancer Treatment, Lung Cancer Treatment, Renal Cell Carcinoma Treatment
2) By Herceptin: Breast Cancer Treatment, Gastric Cancer Treatment
3) By Keytruda: Melanoma Treatment, Non-Small Cell Lung Cancer (NSCLC) Treatment, Head And Neck Cancer Treatment
4) By Opdivo: Melanoma Treatment, Renal Cell Carcinoma Treatment, Hodgkin Lymphoma Treatment
5) By Darzalex: Multiple Myeloma Treatment, AL Amyloidosis Treatment
6) By Perjeta: Breast Cancer Treatment, Neoadjuvant Therapy For HER2-Positive Breast Cancer
7) By Others: Cetuximab (Erbitux) For Colorectal And Head And Neck Cancers, Rituximab (Rituxan) For Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia, Atezolizumab (Tecentriq) For Various Cancers For further insights on the Cancer Monoclonal Antibodies market, request a sample here

North America was the largest region in the cancer monoclonal antibodies market in 2024. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Cancer Monoclonal Antibodies market, request a sample here.

Major companies operating in the cancer monoclonal antibodies market include F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc, Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Gilead Sciences, Eurofarma, BIONOVIS BRASIL, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, 54gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme . For further insights on the Cancer Monoclonal Antibodies market, request a sample here.

Major trends in the Cancer Monoclonal Antibodies market include Collaborative Innovation To Develop Breakthrough Therapies. For further insights on the Cancer Monoclonal Antibodies market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Cancer Monoclonal Antibodies Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top